BAY 1135626

BAY 1135626 用于合成 BAY 1129980，用于抗肿瘤研究。BAY 1129980 是一种基于 Auristatin 的 ADC 试剂，具有抗 C4.4A (LYPD3) 作用，可用于非小细胞肺癌 (NSCLC) 的研究。 在溶剂中：-80°C，6个月-20°C，1个月（避光） BAY 1135626 is used to synthesize BAY 1129980 for anti-tumor research. BAY 1129980 is an ADC reagent based on Auristatin, which has anti-C4.4A (LYPD3) activity and can be used for research on non-small cell lung cancer (NSCLC). In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) In vitro research C4.4A (LYPD3) is a protein expressed in non-small cell lung cancer (NSCLC), with scarcely expressing in normal tissues.BAY 1135626 can be synthesized into BAY 1129980 (C4.4A-ADC), shows a strong anti-proliferative effect on C4.4A expressing cell lines.BAY 1129980 (0.001-100 nM; 72 h) inhibits the proliferation of A549 lung cancer cell lines transfected with C4.4A.BAY 1129980 (0.001-100 nM; 72 h) exhibits high and selective efficacy on hC4.4A:A549 cells in vitro. In vivo research BAY 1129980 (1.9-7.5 mg/kg; i.v.; 20 d) inhibits tumor growth in vivo in mouse.BAY 1129980 with a repeated dosing (15 mg/kg; i.v.; 21 d for 1st cycle and 57 d for 2nd cycle) is well tolerated without changing the sensitivity to the treatment.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet